These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28625716)

  • 81. Genetic Knockdown and Pharmacologic Inhibition of Hypoxia-Inducible Factor (HIF) Hydroxylases.
    Pickel C; Taylor CT; Scholz CC
    Methods Mol Biol; 2018; 1742():1-14. PubMed ID: 29330785
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Stimulating retinal blood vessel protection with hypoxia-inducible factor stabilization: identification of novel small-molecule hydrazones to inhibit hypoxia-inducible factor prolyl hydroxylase (an American Ophthalmological Society thesis).
    Sears JE; Hoppe G
    Trans Am Ophthalmol Soc; 2013 Sep; 111():169-79. PubMed ID: 24385673
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
    Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
    ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway.
    Lee HY; Lee T; Lee N; Yang EG; Lee C; Lee J; Moon EY; Ha J; Park H
    Carcinogenesis; 2011 May; 32(5):703-12. PubMed ID: 21335603
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
    Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
    J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 87. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.
    Haase VH
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S110-S124. PubMed ID: 28449418
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
    Beck H; Jeske M; Thede K; Stoll F; Flamme I; Akbaba M; Ergüden JK; Karig G; Keldenich J; Oehme F; Militzer HC; Hartung IV; Thuss U
    ChemMedChem; 2018 May; 13(10):988-1003. PubMed ID: 29485740
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inhibition of oxygen-sensing prolyl hydroxylases increases lipid accumulation in human primary tubular epithelial cells without inducing ER stress.
    Schley G; Grampp S; Goppelt-Struebe M
    Cell Tissue Res; 2020 Jul; 381(1):125-140. PubMed ID: 32189058
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
    Macdougall IC
    Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):399-405. PubMed ID: 35894273
    [TBL] [Abstract][Full Text] [Related]  

  • 91. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
    Flamme I; Ellinghaus P; Urrego D; Krüger T
    PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Substrate preference of the HIF-prolyl hydroxylase-2 (PHD2) and substrate-induced conformational change.
    Pektas S; Knapp MJ
    J Inorg Biochem; 2013 Sep; 126():55-60. PubMed ID: 23787140
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prolyl-4-hydroxylases 2 and 3 control erythropoietin production in renin-expressing cells of mouse kidneys.
    Broeker KAE; Fuchs MAA; Schrankl J; Lehrmann C; Schley G; Todorov VT; Hugo C; Wagner C; Kurtz A
    J Physiol; 2022 Feb; 600(3):671-694. PubMed ID: 34863041
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U
    PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
    Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
    Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Screening of prolyl hydroxylase 2 inhibitors based on quantitative strategy of peptides.
    Zhang Y; Nsanzamahoro S; Wang CB; Wang WF; Yang JL
    J Chromatogr A; 2022 Aug; 1679():463411. PubMed ID: 35973337
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of HIF-PHD inhibitors in kidney development.
    Haraguchi S; Tsuji K; Nakanoh H; Fukushima K; Kitamura S; Wada J
    Nephrol Dial Transplant; 2024 Jul; 39(8):1368-1370. PubMed ID: 38553963
    [No Abstract]   [Full Text] [Related]  

  • 99. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Hypoxia signaling in renal pericytes-is it safe to activate?
    Herbek S; Edmonston DL; Souma T
    Kidney Int; 2021 Jun; 99(6):1267-1269. PubMed ID: 34023026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.